DDO-2213

Overview

DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC 50 of 29 nM and a K d value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > WDR5

Product Information

• Catalog No.: HY-153331
• CAS No.: 2378768-36-4
• Molecular Formula: C24H27ClFN7O
• Molecular Weight: 483.97
• Purity: 98.84%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source